Patents by Inventor Beate Diefenbach
Beate Diefenbach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220098296Abstract: IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.Type: ApplicationFiled: July 27, 2021Publication date: March 31, 2022Inventors: Michael Otto BARDROFF, Barbara BRANNETTI, Emma Michelle CAMPBELL, Beate DIEFENBACH-STREIBER, Adina EBERTH, Christian Carsten Silverster KUNZ, Sylwia MARSHALL, Jean-Michel Rene RONDEAU, Jean-Marc Alfred SCHLAEPPI, Gino Anselmus VAN HEEKE
-
Patent number: 11111293Abstract: Interleukin-18 (IL-18) participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.Type: GrantFiled: August 24, 2018Date of Patent: September 7, 2021Assignee: NOVARTIS AGInventors: Michael Otto Bardroff, Barbara Brannetti, Emma Michelle Campbell, Beate Diefenbach-Streiber, Adina Eberth, Christian Carsten Silverster Kunz, Sylwia Marshall, Jean-Michel Rene Rondeau, Jean-Marc Alfred Schlaeppi, Gino Anselmus Van Heeke
-
Patent number: 10407496Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.Type: GrantFiled: November 17, 2016Date of Patent: September 10, 2019Assignee: Novartis AGInventors: Beate Diefenbach-Streiber, Adina Eberth, Braydon Charles Guild, Yong-In Kim, Michael Roguska, Igor Splawski
-
Publication number: 20190085068Abstract: IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.Type: ApplicationFiled: August 24, 2018Publication date: March 21, 2019Applicant: NOVARTIS AGInventors: Michael Otto BARDROFF, Barbara BRANNETTI, Emma Michelle CAMPBELL, Beate DIEFENBACH-STREIBER, Adina EBERTH, Christian Carsten Silverster KUNZ, Sylwia MARSHALL, Jean-Michel Rene RONDEAU, Jean-Marc Alfred SCHLAEPPI, Gino Anselmus VAN HEEKE
-
Patent number: 10081677Abstract: Interleukin-18 (IL-18) participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.Type: GrantFiled: May 25, 2016Date of Patent: September 25, 2018Assignee: NOVARTIS AGInventors: Michael Otto Bardroff, Barbara Brannetti, Emma Michelle Campbell, Beate Diefenbach-Streiber, Adina Eberth, Christian Carsten Silverster Kunz, Sylwia Marshall, Jean-Michel Rene Rondeau, Jean-Marc Alfred Schlaeppi, Gino Anselmus Van Heeke
-
Publication number: 20170322204Abstract: The present invention provides methods, immunoassays, kits and devices pertaining to the detection of multiple biomolecules from single cells or other biological entities. It also enables the highly parallel detection of interacting biomolecules from such entities.Type: ApplicationFiled: July 26, 2017Publication date: November 9, 2017Inventors: Markus Enzelberger, Andreas Boll, Beate Diefenbach-Streiber, Guenter Roth, Felix von Stetten, Fabian Stumpf
-
Publication number: 20170260260Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.Type: ApplicationFiled: November 17, 2016Publication date: September 14, 2017Inventors: Beate DIEFENBACH-STREIBER, Adina EBERTH, Braydon Charles GUILD, Yong-In KIM, Michael ROGUSKA, Igor SPLAWSKI
-
Publication number: 20160376361Abstract: IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.Type: ApplicationFiled: May 25, 2016Publication date: December 29, 2016Applicant: NOVARTIS AGInventors: Michael Otto Bardroff, Barbara Brannetti, Emma Michelle Campbell, Beate Diefenbach-Streiber, Adina Eberth, Christian Carsten Silverster Kunz, Sylwia Marshall, Jean-Michel Rene Rondeau, Jean-Marc Alfred Schlaeppi, Gino Anselmus Van Heeke
-
Patent number: 9376489Abstract: Interleukin 18 (IL-18) participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.Type: GrantFiled: September 4, 2013Date of Patent: June 28, 2016Assignee: Novartis AGInventors: Michael Otto Bardroff, Barbara Brannetti, Emma Michelle Campbell, Beate Diefenbach-Streiber, Adina Eberth, Christian Carsten Silvester Kunz, Sylwia Marshall, Jean-Michel Rene Rondeau, Jean-Marc Alfred Schlaeppi, Gino Anselmus Van Heeke
-
Publication number: 20160031975Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.Type: ApplicationFiled: April 28, 2015Publication date: February 4, 2016Applicant: NOVARTIS AGInventors: Beate DIEFENBACH-STREIBER, Adina EBERTH, Braydon Charles GUILD, Yong-In KIM, Michael ROGUSKA, Igor SPLAWSKI
-
Patent number: 8883158Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.Type: GrantFiled: July 25, 2012Date of Patent: November 11, 2014Assignee: Novartis AGInventors: Beate Diefenbach-Streiber, Adina Eberth, Braydon Charles Guild, Yong-In Kim, Michael Roguska, Igor Splawski
-
Publication number: 20140112915Abstract: IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.Type: ApplicationFiled: September 4, 2013Publication date: April 24, 2014Inventors: Michael Otto Bardroff, Barbara Brannetti, Emma Michelle Campbell, Beate Diefenbach-Streiber, Adina Eberth, Christian Carsten Silvester Kunz, Sylwia Marshall, Jean-Michel Rene Rondeau, Jean-Marc Alfred Schlaeppi, Gino Anselmus Van Heeke
-
Publication number: 20140011698Abstract: The present invention provides methods, immunoassays, kits and devices pertaining to the detection of multiple biomolecules from single cells or other biological entities. It also enables the highly parallel detection of interacting biomolecules from such entities.Type: ApplicationFiled: November 30, 2011Publication date: January 9, 2014Applicants: MorphoSys AG, ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG, HSG-IMIT Institut für Mikro-und InformationstechnikInventors: Markus Enzelberger, Andreas Boll, Beate Diefenbach-Streiber, Guenter Roth, Felix von Stetten, Fabian Stumpf
-
Patent number: 8486661Abstract: The present invention relates to antibodies against sclerostin and compositions and methods of use for said antibodies to treat a pathological disorder that is mediated by sclerostin or disease related to bone abnormalities such as osteoporosis.Type: GrantFiled: July 12, 2012Date of Patent: July 16, 2013Assignee: Novartis AGInventors: Michaela Kniessel, Christine Halleux, Shou-Ih Hu, Beate Diefenbach-Streiber, Josef Prassler
-
Publication number: 20130064836Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.Type: ApplicationFiled: July 25, 2012Publication date: March 14, 2013Inventors: Beate DIEFENBACH-STREIBER, Adina EBERTH, Braydon Charles GUILD, Yong-In KIM, Michael ROGUSKA, Igor SPLAWSKI
-
Publication number: 20130022615Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.Type: ApplicationFiled: June 28, 2012Publication date: January 24, 2013Inventors: Beate DIEFENBACH-STREIBER, Adina EBERTH, Braydon Charles GUILD, Yong-In KIM, Michael ROGUSKA, Igor SPLAWSKI
-
Publication number: 20120276591Abstract: The present invention relates to antibodies against sclerostin and compositions and methods of use for said antibodies to treat a pathological disorder that is mediated by sclerostin or disease related to bone abnormalities such as osteoporosis.Type: ApplicationFiled: July 12, 2012Publication date: November 1, 2012Inventors: Michaela Kneissel, Christine Halleux, Shou-Ih Hu, Beate Diefenbach-Streiber, Josef Prassler
-
Patent number: 8246953Abstract: The present invention relates to antibodies against sclerostin and compositions and methods of use for said antibodies to treat a pathological disorder that is mediated by sclerostin or disease related to bone abnormalities such as osteoporosis.Type: GrantFiled: November 11, 2010Date of Patent: August 21, 2012Assignee: Novartis AGInventors: Michaela Kniessel, Christine Halleux, Shou-Ih Hu, Beate Diefenbach-Streiber, Josef Prassler
-
Patent number: 8241628Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.Type: GrantFiled: August 4, 2009Date of Patent: August 14, 2012Assignee: Novartis AGInventors: Beate Diefenbach-Streiber, Adina Eberth, Braydon Charles Guild, Yong-In Kim, Michael Roguska, Igor Splawski
-
Patent number: 8067197Abstract: The invention relates to a novel purified recombinant ?V?3 adhesion receptor which shows an unimpaired ligand binding activity, and a process for preparing said soluble non-membrane bound receptor in excellent yields by recombinant techniques using a baculovirus-insect cell expression system. The so-synthesized soluble receptor may be used very easily as screening tool for new therapeutic compounds which may inhibit the natural ?V?3 adhesion receptor. Such therapeutic compounds which can be discovered very easily, fast and without health risk by means of the soluble receptors according to the invention may be, for example, RGD peptides or non-peptidic compounds mimicking the natural ligand epitopes. The invention relates, furthermore, to a corresponding process for preparing recombinant full-length ?V?3 adhesion receptor in excellent yields, additionally using detergents to dissolve the membrane bound receptor from the surface of the host cell.Type: GrantFiled: June 13, 2003Date of Patent: November 29, 2011Assignee: Merck Patent GmbHInventors: Simon L. Goodman, Beate Diefenbach, Detelv Güssow, Raj Mehta, Eilish Cullen, Alex Brown